Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.75 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.66 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064870 | 0.87 | HDAC1 (0.68) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL1065365 | 0.85 | HDAC1 (0.81) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL1060512 | 0.83 | HDAC1 (0.67) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL23746024 | 0.83 | HDAC1 (0.90) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL1064283 | 0.83 | HDAC1 (0.79) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL1062263 | 0.83 | HDAC1 (0.76) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL1064968 | 0.83 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL8348463 | 0.82 | HDAC1 (0.83) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL1064771 | 0.82 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL675168 | 0.82 | HDAC1 (0.76) | HDAC1HDAC2HDAC3NCOR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| US-20060058298-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20050288282-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6897220-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2005-05-24 | — | — | US | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288282-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC2 5/4885HDAC3 3/4885 |
| US-20060058298-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC2 5/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.